Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Amgen Selects West’s Daikyo Crystal Zenith Vials | Contract Pharma

What are you searching for?

Sign in

Amgen Selects West’s Daikyo Crystal Zenith Vials

Offers break-resistant alternative to glass for complex drugs

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Amgen has selected West’s Daikyo Crystal Zenith (CZ) vials, in conjunction with West FluroTec stoppers, to contain its FDA-approved therapy IMLYGIC (talimogene laherparepvec), indicated for nodal lesions in patients with melanoma. CZ vials are manufactured from a cyclic olefin polymer and offer a break-resistant, high-performance alternative to glass for complex drugs.


 












The CZ container closure system also includes a West FluroTec stopper, which provides a barrier against extractables without compromising seal integrity, according to the company, maintaining the full strength of biologic therapies. Additionally, the CZ vial can withstand cold storage environments.
 
“West recognizes the growing demand for high quality and technologically advanced containment systems for today’s sophisticated biologic drugs, particularly when there may be challenges of interaction or adsorption related to traditional glass vials,” said John Paproski, senior vice president and chief technology officer, West. “Daikyo Crystal Zenith technology represents an important way to address the needs of our customers in this growing biotechnology market.”
 
“We appreciate the relationship we have with West and how they have worked with us to provide an appropriate container closure solution to address the ultra-cold storage conditions for IMLYGIC,” said Bill Rich, vice president, Device Technologies at Amgen.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics